Results for tag: "Inopulse"

INOpulse is a type of cardiovascular drug used to treat pulmonary arterial hypertension (PAH). It is a form of inhaled nitric oxide (iNO) therapy, which works by delivering a precise dose of nitric oxide directly to the lungs. This helps to relax the pulmonary arteries, allowing for improved blood flow and oxygen delivery to the lungs. INOpulse is the only FDA-approved iNO therapy for PAH and is used to treat adults with the condition. INOpulse is a relatively new form of cardiovascular drug, and is still in the early stages of development. It is being studied in clinical trials to assess its safety and efficacy in treating PAH. The drug is also being studied for its potential to treat other cardiovascular conditions, such as chronic thromboembolic pulmonary hypertension (CTEPH). Some companies in the INOpulse market include Bellerophon Therapeutics, Inc., Vectura Group plc, and United Therapeutics Corporation. These companies are involved in the development, manufacture, and marketing of INOpulse and other iNO therapies. Show Less Read more